August 22, 2019 Astra could use a voucher to cement roxadustat’s head start Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
January 15, 2019 Topping 2018 drug approvals will be a tall order Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
